HC Wainwright & Co. Maintains Buy on Palisade Bio, Lowers Price Target to $5
Benzinga Newsdesk 36 minutes ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Palisade Bio (NASDAQ:PALI) with a Buy and lowers the price target from $7 to $5.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Palisade Bio (NASDAQ:PALI) with a Buy and lowers the price target from $7 to $5.